Compare Google Inc (GOOG) vs Summit Therapeutics Inc (SMMT) Price & Performance

Alphabet (GOOG) trades at $344.86, down 0.72% on the day, with strong technical support at $342 and resistance at $348. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $435.24 consensus price target, representing 26% upside potential.

The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors should monitor elevated capital expenditures and potential regulatory risks. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, with upcoming Q3 earnings on October 31, 2026, serving as the next key catalyst.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.